CNS reported a decrease in losses from $3.8 million in Q2 2021 to $3.6 million in Q2 2022, as well as a drop in research and development expenses from $2.7 million to $2.2 million, with an increase in general and administrative expenses from $1.1 million to $1.3 million The company closed the quarter with $9.0 … Continue reading “CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Posts Slight Q2 2022 Performance Improvement; Maintains Priorities and Focus on Advancing its Clinical Development Program for Berubicin”
When CNS went public in 2019, the funds went primarily into pre-clinical preparation, trial design approval, and drug manufacturing for its potentially pivotal global clinical trial of Berubicin for recurrent glioblastoma multiforme (“GBM”) So far, CNS has received FDA Fast Track Designation on its Berubicin clinical study, inching the company closer to offering a viable … Continue reading “CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), Moving the Needle in GBM and Brain Cancer Research”
CNS Pharmaceuticals is currently undertaking a potentially pivotal global study evaluating the efficacy and safety of Berubicin compared with Lomustine administered after first-line therapy for the treatment of recurrent glioblastoma multiforme (“GBM”) GBM is an aggressive form of cancer that occurs in the brain or spinal cord In the U.S., it affects between 12,000-15,000 new … Continue reading “CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Looking to Fill Glioblastoma Multiforme Treatment Gap with Berubicin Drug Product”
CNS Pharmaceuticals (NASDAQ: CNSP) is focused on advancing its clinical program for treating glioblastoma (“GBM”), a brain cancer that has no present cure and few treatment options for patients. The most aggressive primary brain tumor, GBM affects approximately 13,000 new patients each year in the United States with an average survival time of less than … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Continues Priority to Advance Clinical Development Program for Berubicin”
CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today reported its financial results for the quarter ended June 30, 2022, and provided a clinical update of its anti-cancer drug candidates currently in development. “Within … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q2 2022 Financial Results, Corporate Update”
CNS Pharmaceuticals (NASDAQ: CNSP) is currently recruiting patients for a phase II study evaluating the efficacy and safety of Berubicin, its lead drug candidate for treating glioblastoma multiforme (“GBM”), the most aggressive, deadly and treatment-resistant type of cancer that forms in the brain. Recently, the company announced that the FDA had approved an amendment to … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Positioning Berubicin Clinical Development Program for Success”
CNS Pharmaceuticals is a U.S.-based drug innovator developing novel chemotherapy agents capable of taking the fight against cancerous tumors across the blood-brain barrier to directly attack cancerous growths of the central nervous system The company’s lead candidate is an anthracycline named Berubicin, which has previously shown promise among glioblastoma (“GBM”) patients in a safety study … Continue reading “CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Advances Drug Candidate to Fight Aggressive Brain Cancer Amid Difficult Era for Market”
CNS Pharmaceuticals is undertaking a Berubicin clinical development program targeting glioblastoma multiforme (“GBM”), the most common and devastating primary malignant brain tumor GBM has an incidence rate of 3.21 per 100,000 in the U.S. and up to 5 per 100,000 globally, with studies noting that the latter figure is rising CNS recently received approval for … Continue reading “CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Expanding Scope of Potentially Pivotal Study as Part of Clinical Program to Develop GBM Treatment”
CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today urged shareholders to vote in favor of the proposals outlined in its definitive proxy statement for the upcoming annual shareholder meeting to be held Wednesday, … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Urges Shareholders to Vote in Favor of Proxy Proposals for Upcoming Annual Meeting”
CNS Pharmaceuticals (NASDAQ: CNSP) recently announced that its global clinical trial for a potentially pivotal brain cancer treatment will expand patient eligibility following an amendment to its protocol for the study. “CNS has been enrolling patients in its phase II clinical trial for novel drug candidate Berubicin, which has shown promise in fighting the aggressive … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Expanding Patient Eligibility in Potentially Pivotal Berubicin Trial”
